Last updated: April 24, 2026
Which Companies Supply Buprenorphine for Pharmaceuticals?
Buprenorphine supply chains typically split into two tiers: (1) API (active pharmaceutical ingredient) manufacturers and (2) drug-product or intermediate suppliers that prepare finished dosage forms or controlled intermediates. The exact supplier roster depends on the dosage form (Sublingual film/tablet vs buccal film vs injectable), target market, and whether the product is branded or generic. Publicly available procurement and regulatory datasets also show that buprenorphine is supplied by a small set of long-running API and dosage-form manufacturers, plus multiple secondary players that distribute API for formulation.
Who are the major API manufacturers that supply buprenorphine?
The following suppliers are repeatedly cited in regulatory and product supply contexts for buprenorphine-based medicines (API and/or defined buprenorphine substances used in drug manufacture):
| Supplier / Company |
Common role in the buprenorphine value chain |
Evidence type used in market/regulatory practice |
| Indivior |
Brand owner and product supply for buprenorphine-based medicines |
Company product portfolio and regulatory filings across buprenorphine brands (e.g., Suboxone-related lines) |
| Sandoz |
Generic supplier/distributor of buprenorphine-containing products |
Generic market participation and regulatory product listings |
| Teva |
Generic supplier of buprenorphine-containing products |
Generic market participation and regulatory product listings |
| Bausch Health (Endo/Former divisions) |
Branded/generic supply participation depending on geography and product |
Product portfolio and market listings for buprenorphine formulations |
| Aurobindo Pharma |
Generic supplier of buprenorphine formulations |
Generic market participation and regulatory product listings |
| Mylan / Viatris |
Generic supplier/distributor of buprenorphine-containing products |
Generic market participation and regulatory product listings |
| Dr. Reddy’s Laboratories |
Generic supplier of buprenorphine formulations |
Generic market participation and regulatory product listings |
| Hikma |
Generic supplier of buprenorphine formulations |
Generic market participation and regulatory product listings |
Important sourcing detail: many API names above represent finished-product suppliers (tablets/films/injectables) in practice, not always direct API manufacturing entities. In buprenorphine markets, finished-product companies commonly source API from contracted API plants and then manufacture/pack the dosage forms under their own quality system.
Which API manufacturers are most visible for buprenorphine in regulator-facing datasets?
Across global drug supply and inspection ecosystems, buprenorphine API is produced by a limited set of chemical/pharma sites that have sustained controlled-substance manufacturing capability. The most visible API manufacturers in these ecosystems include:
- Hetero Labs (Hetero Drugs)
- Zydus (Cadila / Zydus Lifesciences)
- Cadila Pharmaceuticals (as part of the Cadila group footprint)
- Sun Pharma / Sun (site-dependent)
- Lupin (site-dependent)
- Aurobindo (site-dependent)
- Dr. Reddy’s (site-dependent)
These groups supply buprenorphine either directly as API or as part of a contract manufacturing arrangement for drug-product manufacturers.
How suppliers differ by dosage form (what you actually buy)
Buprenorphine supplier lists change by product type because the supply chain shifts from API-only to dosage-form manufacturing:
- Sublingual tablets/films: typically supplied by generic and branded dosage-form manufacturers that contract API and then do formulation, coating, and packaging.
- Buccal films: concentrated among a smaller set of formulation-capable companies with film manufacturing capacity and controlled packaging supply chains.
- Injectables: far fewer suppliers due to sterile manufacturing capacity and additional regulatory controls.
What procurement structures dominate in buprenorphine?
Most manufacturers procure buprenorphine through one of these structures:
- Direct API purchase from an approved API plant (controlled-substance qualified)
- Contract API + formulation (integrated CDMO covering API procurement, formulation, and packaging)
- Finished-product supply via marketing authorization holders (who may source API from multiple qualified vendors)
For business planning, the “supplier” that matters is usually the entity that can deliver a commercially released dosage form in the target market, with traceable lot release and regulatory documentation.
What regulatory and listing systems identify buprenorphine suppliers?
Which databases firms use to validate buprenorphine sourcing?
Drug sourcing and supplier validation for controlled substances relies on:
- FDA Orange Book: identifies marketing authorization holders for buprenorphine drug products and links to manufacturing/labeling info where applicable (product level, not always API plant level). [1]
- DEA (US) controlled substance registries: govern supplier authorization for controlled manufacturing/handling in the US (person/company registration, not necessarily API manufacturing site visibility in public lists). [2]
- EMA/EEA regulatory product databases: identify marketing authorizations and applicant holders for buprenorphine medicines (again product level). [3]
- WHO ATC/INN references: standardizes substance identity, supports cross-referencing product dossiers to substance naming. [4]
Which companies are the key “buy-side” suppliers in the US for buprenorphine products?
Who supplies buprenorphine-based medicines in major markets (typical market makers)?
The public US market for buprenorphine formulations typically includes:
- Indivior (brand and product supply footprint)
- Sandoz
- Teva
- Viatris (Mylan)
- Aurobindo Pharma
- Dr. Reddy’s
- Hikma
- Bausch Health (depending on product line and geography)
These companies appear as marketing authorization holders or active suppliers in regulatory product listings and commercial distribution for buprenorphine formulations. [1]
What does “supplier” mean for buprenorphine procurement in practice?
Are you buying API, intermediates, or finished dosage forms?
Most R&D and commercial buyers segment supplier qualification by deliverable:
- API supplier qualification: controlled manufacturing, GMP release, impurity profile management, and auditability of the API site
- Intermediate supplier qualification: only used when the buyer controls more of the conversion steps; more common in long-cycle scale-up where the API plant is a bottleneck
- Finished dosage-form supplier qualification: GMP for finished product, packaging control for controlled distribution, and lot release aligned to market authorization
Because buprenorphine is a controlled substance, supplier qualification commonly requires additional compliance steps and documentation (DEA registration in the US) beyond standard GMP supplier onboarding. [2]
Key Takeaways
- Buprenorphine supply is concentrated in a limited number of dosage-form and API supply ecosystems, with finished-product suppliers dominating the visible market lists.
- Indivior and major generic marketers including Sandoz, Teva, Viatris, Aurobindo, Dr. Reddy’s, Hikma, and others typically appear as key product suppliers in regulated markets. [1]
- The most business-relevant “supplier” for delivery risk is usually the marketing authorization holder or dosage-form manufacturer in the target jurisdiction, not the upstream API plant.
- Validation uses FDA Orange Book (product-level) and controlled-substance compliance registries such as DEA (US). [1,2]
FAQs
1) Who is the biggest branded supplier of buprenorphine products?
Indivior is a major branded supplier through its buprenorphine portfolio in regulated markets. [1]
2) Can I find buprenorphine API plant suppliers directly from FDA listings?
Often not at a granular API-plant level. FDA Orange Book identifies marketing authorization holders and product-level details; API manufacturer attribution can be incomplete publicly. [1]
3) Which tool best validates a US-controlled substance supply chain?
DEA controlled substance registration systems validate authorized entities for manufacturing/handling in the US. [2]
4) Do generic companies always manufacture buprenorphine tablets or films themselves?
Not necessarily. Generic marketers commonly contract formulation/production to qualified manufacturers while sourcing API from approved plants. This is why product-level suppliers matter for commercial delivery. [1]
5) What changes most when moving between US, EU, and other markets?
The supplier roster changes by marketing authorization holder and locally approved dosage-form manufacturers. Product dossiers and applicant holders drive visibility more than upstream API sites. [1,3]
References (APA)
[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA / Orange Book (buprenorphine listings). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Drug Enforcement Administration. (n.d.). DEA Diversion Control Division: Registration and controlled substance information. https://www.deadiversion.usdoj.gov/
[3] European Medicines Agency. (n.d.). Find medicine: buprenorphine. https://www.ema.europa.eu/en/medicines
[4] World Health Organization. (n.d.). ATC/DDD and INN substance naming resources. https://www.who.int/teams/health-product-policy-and-standards/inn
